证券代码：603566 证券简称：普莱柯 公告编号：2025-048 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 普莱柯生物工程股份有限公司 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 11 月 27 日 (二)股东大会召开的地点：河南省洛阳市洛龙区政和路 15 号公司二楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 117 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 119,766,328 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 35.0277 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由公司董事会召集，由董事长张许科先生主持，本次会议以现场投票与 网络投票相结合的方式召开，北京德恒律师事务所律师出席了现场会议 ...

Market Review - The agricultural, forestry, animal husbandry, and fishery sector has outperformed the benchmark index since the beginning of 2025, with an absolute return of +24.66%, surpassing the CSI 300 index by 10.47 percentage points [10][17][18] - The sector's index has increased by 18.4% over the past year, outperforming the CSI 300 index by 0.96 percentage points [14] Swine Breeding - The breeding capacity of sows is gradually declining, with a total of 39.9 million sows recorded by the end of October 2025, a year-on-year decrease of 2.04% [27][24] - The average price of live pigs in October 2025 was 11.52 yuan/kg, reflecting a month-on-month decline of 11.46% and a year-on-year drop of 34.77% [29] - The swine breeding industry is currently facing losses, with theoretical profits for self-bred pigs averaging -209.67 yuan/head in October 2025, marking a significant decline from previous months [36][41] - The market share of the top eight listed pig companies has increased from 4.6% in 2017 to 21.2% by the third quarter of 2025, indicating a trend towards industry consolidation [37][41] Animal Health - The animal health market in China has shown steady growth, with sales increasing from 47.23 billion yuan in 2016 to 69.65 billion yuan in 2023, reflecting a compound annual growth rate of 5.71% [45][46] - The introduction of new products and the expansion of demand are driving the growth of the animal health industry, particularly with the anticipated market expansion following the launch of African swine fever vaccines [51][52] - The market for companion animal health products is also growing, with the pet medical market expected to reach approximately 84 billion yuan in 2024, driven by increased spending on veterinary services [56] Seed Industry - The seed industry is experiencing a transformation due to new regulations and policies, with significant investment opportunities arising from the commercialization of biotechnology [4][19] - The market for genetically modified corn is projected to expand, with companies in the sector expected to benefit from increased industry concentration and profitability [18][19] Pet Food - China's pet food market is projected to continue growing, benefiting from demographic changes and rising living standards, with significant potential for domestic brands to capture market share [5][59] - The market for pet food exports is expected to maintain year-on-year growth in 2025, reflecting the increasing demand for high-quality pet products [5][59] - The pet food industry remains fragmented, with ongoing trends towards domestic substitution and increased online sales [5][59]

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on November 24, with *ST Lvkang leading the drop [1][2] Market Performance - The Shanghai Composite Index closed at 3836.77, up 0.05% - The Shenzhen Component Index closed at 12585.08, up 0.37% [1] Individual Stock Performance - Notable gainers in the animal health sector included: - Shenlian Biological (688098) with a closing price of 9.57, up 2.57% on a trading volume of 55,100 shares and a turnover of 52.32 million yuan - Yongshun Biological (920729) at 8.95, up 1.59% with a trading volume of 15,900 shares and a turnover of 14.22 million yuan - Xianfeng Holdings (002141) at 3.98, up 1.53% with a trading volume of 694,200 shares and a turnover of 275 million yuan [1] Capital Flow Analysis - The animal health sector saw a net outflow of 35.49 million yuan from institutional investors, while retail investors contributed a net inflow of 31.36 million yuan [2][3] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [3] Stock-Specific Capital Flow - Key stocks with significant capital flow include: - Dayu Biological (920970) with a net inflow of 1.55 million yuan from institutional investors - Pulaike (603566) with a net inflow of 0.99 million yuan from institutional investors - Shenlian Biological (688098) faced a net outflow of 2.88 million yuan from institutional investors [3]

Core Viewpoint - The stock price of Pulaike has experienced fluctuations, with a recent decline of 2.03% and a year-to-date increase of 11.28% [1][2]. Company Overview - Pulaike Bioengineering Co., Ltd. is located in Luoyang, Henan Province, established on June 22, 2002, and listed on May 18, 2015. The company primarily engages in the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine [2]. - The revenue composition includes: poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [2]. Financial Performance - For the period from January to September 2025, Pulaike achieved operating revenue of 823 million yuan, representing a year-on-year growth of 8.04%. The net profit attributable to the parent company was 157 million yuan, reflecting a significant increase of 47.86% [2]. - Cumulative cash dividends since the A-share listing amount to 1.125 billion yuan, with 568 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders is 16,700, a decrease of 7.26% from the previous period. The average circulating shares per person increased by 7.83% to 20,739 shares [2]. - Among the top ten circulating shareholders, Guotai Zhongzheng Livestock Breeding ETF ranks sixth with 5.4716 million shares, an increase of 2.0217 million shares from the previous period. Hong Kong Central Clearing Limited is the eighth largest shareholder with 3.832 million shares, marking a new entry [3].

Core Viewpoint - On November 20, 2023, the stock of Pulaike experienced a decline of 0.58%, with a trading volume of 43.79 million yuan, indicating a negative trend in market performance [1] Financing Summary - On the same day, Pulaike had a financing buy-in amount of 4.09 million yuan and a financing repayment of 12.67 million yuan, resulting in a net financing outflow of 8.58 million yuan [1] - As of November 20, the total financing and securities lending balance for Pulaike was 135 million yuan, which is 2.82% of its circulating market value, indicating a low financing balance compared to the past year [1] - The company repaid 100 shares of securities lending and sold 700 shares, with a selling amount of 9,674 yuan, while the remaining securities lending volume was 25,700 shares, with a balance of 355,200 yuan, which is above the 50th percentile of the past year [1] Company Overview - Pulaike Bioengineering Co., Ltd. was established on June 22, 2002, and listed on May 18, 2015, primarily engaged in the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine [2] - The revenue composition includes poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [2] - As of September 30, 2023, the number of shareholders was 16,700, a decrease of 7.26%, while the average circulating shares per person increased by 7.83% to 20,739 shares [2] Financial Performance - For the period from January to September 2023, Pulaike achieved an operating income of 823 million yuan, representing a year-on-year growth of 8.04%, and a net profit attributable to shareholders of 157 million yuan, reflecting a significant increase of 47.86% [2] Dividend Information - Since its A-share listing, Pulaike has distributed a total of 1.125 billion yuan in dividends, with 568 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2023, the sixth largest circulating shareholder was the Guotai Zhongzheng Livestock Breeding ETF, holding 5.4716 million shares, an increase of 2.0217 million shares from the previous period [3] - The Hong Kong Central Clearing Limited was the eighth largest circulating shareholder, holding 3.832 million shares as a new shareholder [3]

Core Viewpoint - The animal health sector experienced a slight decline of 0.31% on November 19, with Xianfeng Holdings leading the losses, while the Shanghai Composite Index rose by 0.18% to close at 3946.74 [1]. Group 1: Market Performance - The animal health sector's individual stock performance varied, with notable gainers including Qudongli (up 3.98% to 10.71) and ST Lvkang (up 3.80% to 46.40) [1]. - Conversely, several stocks faced declines, such as Jinhai Biological (down 0.96% to 6.19) and Shunlian Biological (down 1.08% to 10.12) [1][2]. Group 2: Trading Volume and Capital Flow - The total trading volume for the animal health sector was significant, with Qudongli achieving a volume of 34,000 hands and a transaction value of approximately 35.9 million yuan [1]. - The sector saw a net outflow of 49.13 million yuan from institutional investors, while retail investors contributed a net inflow of 548.09 million yuan [2]. Group 3: Individual Stock Capital Flow - Among individual stocks, Shengong Holdings experienced a net outflow of 31.56 million yuan from retail investors, while Biotech Holdings saw a net inflow of 555.72 million yuan from retail investors [3]. - The stock with the highest net inflow from retail investors was Biotech Holdings, with 555.72 million yuan, while the largest net outflow was from Yongshun Biological, totaling 408.61 million yuan [3].

普莱柯生物工程股份有限公司 2025 年第二次临时股东大会会议资料 普莱柯生物工程股份有限公司 2025 年第二次临时股东大会会议须知 为维护投资者的合法权益，确保普莱柯生物工程股份有限公司（以下简称"公 司"）2025 年第二次临时股东大会的正常秩序和议事效率，根据《中华人民共和 国公司法》《公司章程》《公司股东大会议事规则》等有关规定，特制定本次股东 大会会议须知： 普莱柯生物工程股份有限公司 2025 年第二次临时股东大会会议资料 普莱柯生物工程股份有限公司 2025 年第二次临时股东大会会议资料 二 O 二五年十一月 1 一、会议组织 1、公司负责本次会议的程序安排和会务工作，出席会议人员应当听从工作 人员安排，共同维护好会议秩序。 2、为保证本次会议的正常秩序，除出席会议的股东及股东代表、董事、监 事、董事会秘书、高级管理人员以及见证律师以外，公司有权拒绝其他人员进入 会场。对于影响本次会议秩序和损害其他股东合法权益的行为，公司将按规定加 以制止。 3、出席本次会议的股东及股东代表应当按照公司《关于召开 2025 年第二次 临时股东大会的通知》要求，持相关证件办理签到手续。在大会主持人宣布现场 出席 ...

Investment Rating - The report maintains an "Outperform" rating for the agriculture, forestry, animal husbandry, and fishery industry [1]. Core Views - The report highlights a continued decline in pig prices and strong performance in pet food sales during the "Double Eleven" shopping festival [1]. - The industry is currently trading at lower price-to-earnings (P/E) and price-to-book (P/B) ratios compared to historical averages, indicating potential for valuation recovery [1]. Summary by Sections Market Review - In October 2025, the agriculture, forestry, animal husbandry, and fishery index rose by 0.19%, outperforming the CSI 300 index, which had a return of approximately 0% [8][11]. - The pet food sector experienced a decline, while the wood processing sector showed strong gains [11]. Livestock Farming Data Tracking - Pig prices continued to decline in October 2025, with an average price of 11.52 yuan/kg, down 11.46% month-on-month and 34.77% year-on-year [16]. - The average price for white feather broilers was 3.38 yuan/jin, showing a slight decrease of 0.29% month-on-month and 7.65% year-on-year [26]. Pet Food Sales Performance - During the "Double Eleven" period in 2025, total sales of pet food reached 9.4 billion yuan, a year-on-year increase of 59.3% [35]. - Pet food exports in September 2025 totaled 30,500 tons, up 18.78% year-on-year, while the cumulative export amount from January to September was 1.057 billion USD, down 3.73% year-on-year [32][35]. Investment Recommendations - The report suggests focusing on companies such as Muyuan Foods, Pulaike, QiuLe Seed Industry, GuaiBao Pet, ZhongChong Co., and Petty Co., all rated as "Buy" [1].

Core Insights - The animal health sector experienced a decline of 0.24% on November 17, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.68, up 5.12% [1] - *ST Lvkang (code: 002868) with a closing price of 42.57, up 5.01% [1] - Houfeng Holdings (code: 002141) with a closing price of 3.91, up 2.62% [1] - Major decliners included: - Dayu Biological (code: 920970) with a closing price of 8.70, down 3.87% [2] - Ruipu Biological (code: 300119) with a closing price of 20.61, down 2.92% [2] - Zhongmu Co., Ltd. (code: 600195) with a closing price of 7.94, down 1.98% [2] Capital Flow - The animal health sector saw a net outflow of 10.15 million yuan from institutional investors, while retail investors experienced a net outflow of 20.76 million yuan [2] - Conversely, speculative funds recorded a net inflow of 30.91 million yuan [2] Individual Stock Capital Flow - Notable capital flows included: - Biological Shares (code: 600201) with a net inflow of 12.08 million yuan from institutional investors [3] - Xianfeng Holdings (code: 002141) with a net inflow of 9.50 million yuan from institutional investors [3] - Ruipu Biological (code: 300119) with a net inflow of 1.05 million yuan from speculative funds [3] - Decliners in capital flow included: - *ST Lvkang (code: 002868) with a net outflow of 0.79 million yuan from institutional investors [3] - Hai Li Biological (code: 603718) with a net outflow of 2.82 million yuan from institutional investors [3]

（文章来源：证券日报） 证券日报网讯 11月14日晚间，中牧股份发布公告称，公司于2025年11月13日召开第九届董事会2025年 第十三次临时会议审议通过《关于放弃控股子公司股权优先购买权的议案》。公司与普莱柯生物工程股 份有限公司（简称"普莱柯"）、中信农业科技股份有限公司（简称"中信农业"）共同出资成立中普生物 制药有限公司（简称"中普生物"），截至目前中牧股份对其持股48.99%、普莱柯对其持股46.97%、中 信农业对其持股4.04%，中普生物为公司控股子公司。近日，中信农业将其持有中普生物4.04%的股权 以不低于人民币1，751.43万元的价格进行挂牌出让。为进一步优化、布局公司业务，同时根据自身发 展规划，公司拟放弃上述出让股权的优先购买权，由普莱柯或其他第三方摘牌受让股权。同时，公司收 到普莱柯的函件，普莱柯拟行使上述出让股权的认购权，如普莱柯认购成功，中普生物将不再为公司控 股子公司。 ...